Septerna (SEPN) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Septerna (SEPN) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 51.1% versus a loss of 8.6%. Septerna is the larger company by market cap ($1.84 billion vs $1.75 billion), about 1.0 times the size. Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -106.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SEPN | STOK |
|---|---|---|
| Share price | $38.61 | $26.81 |
| Market cap | $1.84B | $1.75B |
| 1-day change | -1.51% | -0.45% |
| YTD return | +38.49% | -15.53% |
| 1-year return | +51.06% | -8.62% |
| 5-year return | — | +6.77% |
| EPS (TTM) | $-1.30 | $-3.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $45.95M | $184.42M |
| Revenue growth (YoY) | +4174.51% | +404.50% |
| Net income (latest FY) | $-48.88M | $-6.88M |
| Operating margin | -148.63% | -11.16% |
| Net margin | -106.37% | -3.73% |
| 52-week high | $53.34 | $40.22 |
| 52-week low | $22.78 | $22.05 |
| Distance from 52-week high | -27.62% | -33.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +53.38% | +73.00% |
| Average volume | 383.96K | 1.02M |
| Shares outstanding | 47.55M | 65.41M |
| Employees | 134 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed STOK by 59.7 percentage points over the past year.
- Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +404.50%).
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
SEPN vs STOK FAQ
Which is bigger, Septerna or Stoke Therapeutics?
Septerna (SEPN) is larger, with a market capitalization of $1.84B compared with $1.75B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, SEPN or STOK?
SEPN returned +51.06% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Septerna and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.